Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Fast oscillations in cortical-striatal networks switch frequency following rewarding events and stimulant drugs.

Berke JD.

Eur J Neurosci. 2009 Sep;30(5):848-59. doi: 10.1111/j.1460-9568.2009.06843.x. Epub 2009 Jul 31.

2.

Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus.

Mason R, Cheer JF.

Front Integr Neurosci. 2009 Jun 15;3:13. doi: 10.3389/neuro.07.013.2009. eCollection 2009.

3.

Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity.

Adermark L, Talani G, Lovinger DM.

Eur J Neurosci. 2009 Jan;29(1):32-41. doi: 10.1111/j.1460-9568.2008.06551.x.

4.

CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors.

Tzavara ET, Degroot A, Wade MR, Davis RJ, Nomikos GG.

Eur Neuropsychopharmacol. 2009 Mar;19(3):196-204. doi: 10.1016/j.euroneuro.2008.11.003. Epub 2008 Dec 29.

PMID:
19116182
5.

The role of CB1 receptors in psychostimulant addiction.

Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ.

Addict Biol. 2008 Jun;13(2):225-38. doi: 10.1111/j.1369-1600.2008.00109.x. Review.

PMID:
18482432
6.

The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus.

Thiemann G, Di Marzo V, Molleman A, Hasenöhrl RU.

Pharmacol Biochem Behav. 2008 May;89(3):384-91. doi: 10.1016/j.pbb.2008.01.010. Epub 2008 Jan 26.

PMID:
18294680
7.

Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant.

Gerdeman GL, Schechter JB, French ED.

Neuropsychopharmacology. 2008 Oct;33(11):2747-59. Epub 2007 Dec 5.

8.

The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.

Thiemann G, van der Stelt M, Petrosino S, Molleman A, Di Marzo V, Hasenöhrl RU.

Behav Brain Res. 2008 Mar 5;187(2):289-96. Epub 2007 Sep 25.

PMID:
17988751
10.

Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants.

Corbillé AG, Valjent E, Marsicano G, Ledent C, Lutz B, Hervé D, Girault JA.

J Neurosci. 2007 Jun 27;27(26):6937-47.

11.

Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM.

J Neurosci. 2007 Jan 24;27(4):791-5.

13.
14.

Transient striatal gamma local field potentials signal movement initiation in rats.

Masimore B, Schmitzer-Torbert NC, Kakalios J, Redish AD.

Neuroreport. 2005 Dec 19;16(18):2021-4.

PMID:
16317346
15.

Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization.

Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA.

Eur Neuropsychopharmacol. 2005 Jan;15(1):31-7.

PMID:
15572271
16.

CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors.

Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M.

Neuropsychopharmacology. 2005 Feb;30(2):339-49.

17.

Oscillatory entrainment of striatal neurons in freely moving rats.

Berke JD, Okatan M, Skurski J, Eichenbaum HB.

Neuron. 2004 Sep 16;43(6):883-96. Erratum in: Neuron. 2004 Oct 28;44(3):571.

18.

The molecular logic of endocannabinoid signalling.

Piomelli D.

Nat Rev Neurosci. 2003 Nov;4(11):873-84. Review. No abstract available.

19.

Robust, automatic spike sorting using mixtures of multivariate t-distributions.

Shoham S, Fellows MR, Normann RA.

J Neurosci Methods. 2003 Aug 15;127(2):111-22.

PMID:
12906941
20.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG.

Br J Pharmacol. 2003 Feb;138(4):544-53.

Supplemental Content

Support Center